analysi nyse
full analysi trefi
found boston scientif corpor develop manufactur
suppli medic devic across world devic primarili
sold follow area medicin intervent cardiolog cardiac
urology/women neuromodul electrophysiolog
compani largest sourc revenu sale intervent cardiolog
cardiac rhythm manag devic
suppli devic around countri around
world mainli europ middl east japan canada china
india brazil compani histor acquisit order
strateg expand oper sale
main competitor johnson johnson medtron abbott
spree acquisit
announc acquisit last year recent
compani close acquisit spine solut maker vertiflex
up-front cash payment million compani expect
acquisit aid long term growth
recent unveil medium long term growth strategi
target double-digit adjust earn growth driven margin
improv compani aim organ revenu compound-annual-growth-rate
time frame
stock strong run saw around growth
year-to-d june compani
strategi grow earn aid stock price move
revenu intervent
revenu endoscopi
revenu urology/women
accru liabil total
liabil revenu
revenu cardiac rhythm
accru liabil total
liabil revenu
summari boston
cardiovascular constitut trefi price estim boston
medsurg constitut trefi price estim boston
rhythm manag constitut trefi price estim
interact valuat breakdown trefi
share price estim overal compani valu deriv
summing-up valu individu divisions/busi sum-of-the-
part analysi valu divis calcul use discount cash
forecast fundament driver like price market share profit
margin differ busi estim divis valu within
dcf framework analysi primarili focus import
forecast drive share price valu estim
complet analysi includ sourc histor data underli
equat addit discuss avail www trefi com
key driver valu present opportun
upsid downsid current trefi price estim compani
cardiovascular revenu import
divis biggest sourc revenu
compani continu innov drug elut stent technolog de
transcathet aortic valv tavr system expect
compani retain market share forecast period
promu premier stent gain widespread accept
meanwhil synergi stent continu perform strongli
repres compani total european de sale
similarli product offer compani structur heart
busi expect sustain grow market share lotu
trefi analysi boston scientif
tavr report impress growth intern
market anoth product could bolster revenu ic divis
watchman devic receiv fda approv
segment largest revenu contributor constitut
price estim even small out-perform respect
expect huge impact compani valuat
medsurg revenu divis second
biggest revenu sourc forecast compani
market share remain steadi result moder growth revenu
segment includ women urolog well
endoscopi busi segment revenu grow fast
pace trend expect continu come year go
ahead compani improv market share significantli
segment revenu increas addit billion end
forecast period upsid price estim
intervent cardiolog endoscopi cardiac rhythm manag
major sourc revenu compani
continu innov product improv
coronari stent implant tube help open block arteri
ensur smooth blood flow largest revenu driver
compani world provid two-
drug platform compani keep launch improv version
stent maintain market leadership posit follow trend
compani launch promu premier element improv version
drug-elut stent de technolog along next
gener line defibril pacemak continu innov
product improv allow maintain healthi
market share increas revenu base divis view
acquisit captur market share
acquisit alway integr part growth
strategi compani acquir sadra medic atritech order
increas market share respect structur heart therapi
atrial fibril busi fall intervent cardiolog
divis also acquir cameron health strengthen sale
cardiac rhythm manag busi
launch new product
spend signific portion revenu research
develop result abl launch mani self-manufactur
trefi analysi boston scientif
product market last year compani launch
new devic major segment instanc compani launch
system europ fuel defibril growth
acquisit segment
follow histor acquisit strategi acquir
sever compani last year order expand product
portfolio recent compani acquir nxthera
million also intend acquir btg plc milliped inc
undertak restructur program aim
improv effici innov help improv market
presenc also cut cost benefit margin
stringent healthcar regul implement check price
structur medic devic compani could neg impact
global revenu growth
full analysi trefi
trefi analysi boston scientif
cardiovascular divis constitut price estim stock base sum part
analysi import driver cardiovascular busi
revenu intervent cardiolog
includ revenu sale product stent cathet remov clog arteri help
restor blood flow throughout bodi
revenu intervent cardiolog increas past year stood billion expect
trend continu go forward
new product synergi de approv fda like help compani gain
market share intervent cardiolog market go ahead synergi stent uniqu polym
stent fulli absorb shortli drug-elut complet hasten heal tissu around stent promu
element improv version compani drug-elut stent de technolog
seek approv larg intern market like japan china india product
launch intern help compani improv market share particularli emerg market
price growth intervent cardiolog market character
constant research develop lead new innov product mani newer product
patent-protect allow manufactur charg premium price help overal price growth
trefi analysi boston scientif
revenu intervent cardiolog
emerg market demand grow patient popul industri begun serv demand
china india brazil revenu go see signific increas addit world
popul increas grow number patient develop cardiovascular diseas due unhealthi lifestyl
expect growth demand
cardiovascular medic devic
competit perform issu stent market highli competit number
compani includ abbott lab etc vy market share addit coronari
stent sale part intervent cardiolog divis suffer recent year due
perform drug-elut stent coronari stent use prevent blockag coronari arteri
sourc histor data explan found trefi com websit link
gross profit defin revenu minu cost good sold gross profit margin defin gross profit divid
gross margin gradual declin due competit price
pressur margin improv consist last year stood forecast gross
margin stabil around forecast period
acquisit could lead higher margin histor acquisit make
acquisit add product portfolio allow sustain healthi margin acquisit
trefi analysi boston scientif
urolog portfolio bayer intervent provid support near-
term compani remain acquisit margin could receiv boost
restructur initi boost margin compani restructur program result signific
cost save provid support margin compani target basi point growth annual
adjust oper margin next year
healthcar reform put pressur margin stringent healthcar regul implement check
price structur medic devic compani put downward pressur revenu
reduc reimburs lead lower revenu healthcar reform result
expans publicli insur base like result lower public reimburs moreov privat insur
compani increas scrutini provid reimburs like affect demand medic
devic constrain revenu go forward
competit lead lower price signific competit medic devic industri result
downward pressur averag sell price turn put pressur compani margin
sourc histor data explan found trefi com websit link
nwc noa alloc
revenu intervent
cardiolog total
capit expenditur total
revenu peripher
intervent total
addit see detail cardiovascular busi appendix link
trefi analysi boston scientif
import driver medsurg busi
revenu endoscopi
revenu urology/women
accru liabil total revenu
liabil revenu
includ revenu sale devic use diagnos treat gastrointestin gi pulmonari
condit use less invas technolog
revenu endoscopi increas moder billion billion go forward
expect figur grow north billion
new product boston scientif launch spyglass visual system treat pancreatico-biliari diseas
compani also expect launch sever product next year help increas
market share
long-term impact acquisit asthmatx asthmatx develop minim invas catheter-bas
technolog treat asthma patient gener prefer least invas product asthmatx could help boston
intern expans boston scientif joint ventur frankenman medic chines medic
devic maker joint ventur like captur share endoscopi market china
trefi analysi boston scientif
revenu endoscopi
market factor europ wit age popul demand endoscopi product
like increas trend coupl grow popul improv healthcar emerg market
boost long-term sale divers use endoscopi equip includ surgic oper well non-surg
oper intern diagnosi anatom observ versatil ensur healthi demand
equip go forward year prefer peopl shift toward minim invas
treatment sinc endoscop devic offer fulfil demand market continu grow endoscopi also
provid measur weight loss rise consumer result increas obes popul
global endoscopi market continu grow
intens competit medic devic industri extrem competit market mani newer
entrant adopt aggress price strategi compani focus cut cost differenti
product order protect share could lose busi lower-cost competitor
sourc histor data explan found trefi com websit link
includ revenu sale devic use treat urolog pelvic condit kidney stone benign
prostat hyperplasia bph erectil dysfunct male incontin pelvic floor disord abnorm uterin bleed
uterin fibroid polyp
revenu urology/women increas last year stood littl billion
expect trend continu
trefi analysi boston scientif
revenu urology/women
portfolio compani sale divis expand significantli sinc go ahead expect
realiz commerci synergi associ acquisit
increas sale compani next-gener endometri ablat system success
bring new busi continu near-term
market factor europ wit age popul
sale urolog devic also increas medicar offer reimburs disabl
year age cathet month extent polici remain place sale remain
strong varieti reason patient gener prefer minim
invas medic procedur newer minimally-invas product introduc drive global sale
sourc histor data explan found trefi com websit link
refer liabil accru compani yet paid forecast accru liabil percentag
accru liabil total revenu past year howev declin
expect remain around current level go forward
expect accru liabil total revenu remain near histor level
sourc histor data explan found trefi com websit link
trefi analysi boston scientif
accru liabil total revenu non-curr liabil revenu refer long-term liabil report
balanc sheet express percentag overal revenu compani give detail around liabil
non-curr liabil revenu increas howev
declin sinc go forward expect figur remain around current level rest
review period
taken histor trend account order make forecast futur
sourc histor data explan found trefi com websit link
analysi gross margin cardiovascular divis
nwc noa alloc
revenu urology/women
total
revenu endoscopi total
capit expenditur total
trefi analysi boston scientif
liabil revenu
addit see detail medsurg busi appendix link
import driver rhythm manag busi
revenu cardiac rhythm manag
includ revenu devic implant cardiovert defibril system implant
period rel mute growth revenu cardiac rhythm manag increas billion
expect figur continu increas go forward slow pace
new product boston scientif number product pipelin launch watchman wit
rapid growth intern market mri approv compani defibril platform expect
soon may drive growth divis newer effect product allow compani protect
share
market factor grow popul health-rel factor emerg market increas
number peopl suffer cardiac diseas addit increas wealth dispos incom allow
trefi analysi boston scientif
revenu cardiac rhythm manag consum market afford healthcar think sever innov product go
launch world-wide next year hint toward demand better improv product
regulatori hurdl regulatori investig depart
justic articl written journal american medic associ jama laid stricter
elig requir use cardiac rhythm manag devic limit like neg
sourc histor data explan found trefi com websit link
analysi gross margin cardiovascular divis
nwc noa alloc
revenu cardiac rhythm
manag total
revenu neuromodul
capit expenditur total
revenu electrophysiolog
total
total
addit see detail rhythm manag busi appendix link
trefi analysi boston scientif
import driver divest busi busi
accru liabil total revenu
liabil revenu
analysi accru liabil total revenu medsurg divis
analysi liabil revenu medsurg divis
analysi gross margin cardiovascular divis
addit see detail divest busi busi appendix link
nwc noa alloc
revenu divest busi
capit expenditur total
total
trefi analysi boston scientif
week free trial trefi
like report get access even comprehens report along interact analys trefi
tri trefi week
trefi com found mit engin former wall street analyst realiz peopl
understand seemingli familiar compani around includ well known compani like googl coca
cola ge ford name
trefi platform use extens data show singl snapshot drive valu compani busi
move beyond qualit notion love coffe dunkin donut think buy
stock answer quantit question like coffe sale next year doughnut sale
happen valu compani
trefi analyst spend week evalu stock cover util commonli use valuat methodolog
determin trefi price compani present synthes view also everi singl
step within valuat process use determin trefi price see via interact analysi
trefi stori
read trefi faq
trefi analysi boston scientif
summari
summari
cardiovascular total
medsurg total
rhythm manag total
divest busi total
cardiovascular total
medsurg total
rhythm manag total
divest busi total
cardiovascular total
medsurg total
rhythm manag total
divest busi total
cardiovascular total
medsurg total
rhythm manag total
divest busi total
cardiovascular total
medsurg total
rhythm manag total
divest busi total
trefi analysi boston scientif
detail cardiovascular
import driver cardiovascular busi discuss detail
prepaid expens revenu
accru liabil total
current liabil
asset revenu
liabil revenu
capital-expenditure
revenu intervent
revenu intervent
revenu peripher
revenu peripher
sg
revenu
trefi analysi boston scientif
royalti expens
detail medsurg busi
import driver medsurg busi discuss detail
prepaid expens revenu
accru liabil total
current liabil
asset revenu
liabil revenu
revenu urology/women
capital-expenditure
revenu endoscopi bil
revenu urology/women
revenu endoscopi bil
trefi analysi boston scientif
sg
revenu
royalti expens
detail rhythm manag
import driver rhythm manag busi discuss detail
prepaid expens revenu
accru liabil total
current liabil
asset revenu
liabil revenu
revenu neuromodul bil
revenu neuromodul
revenu cardiac rhythm
revenu cardiac rhythm
trefi analysi boston scientif
capital-expenditure
revenu electrophysiolog mil
revenu electrophysiolog
sg
revenu
royalti expens
trefi analysi boston scientif
detail divest busi
import driver divest busi busi discuss detail
prepaid expens revenu
accru liabil total
current liabil
asset revenu
liabil revenu
revenu divest busi
revenu divest busi
capital-expenditure
sg
revenu
royalti expens
trefi analysi boston scientif
trefi analysi boston scientif
